David Van Sickle

Engineered for rest. Designed for sleep. Get $50 off Ozlo Sleepbuds® - available now at OzloSleep.com 💤

Were building a new non-invasive breathing monitor to prevent respiratory complications. Our monitors combine breakthroughs in wearable ultrasound with advances in AI/ML, to enable fully-automated, continuous respiratory monitoring.

As the leading global authority on the evolution of digital health technology, Digital Therapeutics Alliance (DTA) is a 501(c)(6) non-profit trade association of industry leaders and stakeholders dedicated to the understanding, adoption, and integration of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors to improve clinical and health economic outcomes. As the leading international organization on digital therapeutic thought leadership and education, DTA provides the digital health ecosystem with the necessary tools to define, evaluate, and utilize DTx products. For more information, please visit: www.dtxalliance.org.

Engineered for rest. Designed for sleep. Get $50 off Ozlo Sleepbuds® - available now at OzloSleep.com 💤

At SHS Capital we are committed to Building European Healthcare Champions, by helping to accelerate our portfolio companies growth. We do that by following high ethical and sustainable standards. If you are looking for the right partner to bring your Healthcare company to the next level, reach out! https://www.shs-capital.eu/ We focus on Phases: Growth cases and “Mittelstand” companies Regions: DACH, Benelux, and the NordicsIndustries: Life science, Medical technology, Diagnostics, Digital health, Applied technologies, and industrial biotechnology & pharmaceuticals (no drug development) Investors can participate in a diversified portfolio of innovative companies from the life science and medical technology sector via SHS funds. Our investor base comprises private and institutional investor groups with a long-term focus. We currently host investors from well-known family offices, pension funds, pension schemes, fund of funds, banks, churches, health insurance companies, industrial companies, the European Investment Fund, and the KfW.

LifeArc Ventures invests in early-stage science-led companies that can benefit from our advice, scientific insight and venture funding. We’re committed to encouraging and financing innovative, early-stage life science companies to help them positively impact the lives of patients. As part of the medical research charity LifeArc, we offer a unique combination of scientific, commercial and financial support. We have access to leading scientists with the skills and expertise to understand translational science at a deep level, enabling us to make educated and informed decisions around our investments, and to help our portfolio companies achieve meaningful progress

Were building a new non-invasive breathing monitor to prevent respiratory complications. Our monitors combine breakthroughs in wearable ultrasound with advances in AI/ML, to enable fully-automated, continuous respiratory monitoring.

Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. The nine-month program employs an objectives-based mentoring process to enhance the performance of technical founders who learn from the insights of experienced entrepreneurs, with the goal of maximizing equity-value creation. Founded by Professor Ajay Agrawal in 2012 at the University of Toronto’s Rotman School of Management, the program has expanded and now has 11 sites across six countries: Toronto, Vancouver, Calgary, Montreal, Halifax, Paris, Madison, Seattle, Estonia, Berlin, and Melbourne. The program combines 5 elements to help companies transition from science projects to scalable and financeable companies: - An emphasis on objective-setting, helping companies focus on what’s most important to their business - Focused mentorship from experienced entrepreneurs who have founded, led, and sold significant tech companies - Technical advice from world-leading scientists, engineers, and economists - Hands-on support from top business students, who embed within the company to provide business support - Opportunities to raise capital, including angels and VCs from Europe and North America The successful commercialization of cutting-edge science and technology achieved through the program has led to the creation of over CAD $35 billion in equity value.